Altimmune, Inc. Announces Resignation of Sybil Tasker as Chief Medical Officer, Effective June 30, 2019
June 07, 2019 at 04:02 pm EDT
Share
On June 3, 2019, Sybil Tasker, M.D., MPH notified Altimmune, Inc. of her resignation as Chief Medical Officer of the Company, effective as of June 30, 2019. To facilitate an orderly transition, Dr. Tasker is expected to provide consulting services to the Company through December 31, 2019. The Company has commenced a search for Dr. Tasker's replacement.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE, INC. 
